Clinical reference Biomarker Directory
Back to directory

COL9A1

Emerging

COL9A1 mutations cause multiple epiphyseal dysplasia, a skeletal cartilage growth disorder, diagnosed via genetic testing.

Also known as Collagen type IX alpha 1
In plain language

This gene makes part of the collagen that gives cartilage its structure. Mutations cause a skeletal growth disorder affecting the joints, and variations in this gene are also being studied for a possible role in back disc problems, more as a research topic than a treatment-guiding blood test.

Biomarker & context

COL9A1 encodes a component of type IX collagen, an important structural protein in cartilage that helps organize the cartilage extracellular matrix.

What it indicates

Mutations in COL9A1 cause multiple epiphyseal dysplasia, a skeletal growth disorder affecting joint cartilage development, and variants have also been studied in relation to intervertebral disc degeneration susceptibility.

Diagnosis & clinical testing

Diagnosed via genetic testing (COL9A1 sequencing) in patients with characteristic joint pain, early-onset osteoarthritis, and skeletal imaging findings suggestive of epiphyseal dysplasia; disc degeneration association studies remain primarily in the research domain.

Guiding treatment

No COL9A1-specific therapy exists; management of multiple epiphyseal dysplasia is supportive (pain management, orthopedic monitoring, and joint replacement in severe adult cases), with genetic counseling for affected families.

Clinical significance

More of a genetic/research marker than a routine clinical blood test; disc degeneration link remains investigational.

References
  1. General genetics/orthopedics reference literature on COL9A1 mutations in multiple epiphyseal dysplasia.